Used in targeted cancer immunotherapy, particularly for hematological malignancies expressing LY75 (CD205), this reference antibody serves as a critical tool in the development of antibody-drug conjugates (ADCs). It enables selective delivery of cytotoxic agents to LY75-positive tumor cells, such as certain B-cell lymphomas and dendritic cell leukemias, minimizing damage to healthy tissues. Due to its high specificity, it supports research in immune cell targeting, antigen presentation pathways, and therapeutic efficacy evaluation. It is also employed as a benchmark in preclinical studies for comparing novel anti-LY75 therapeutics and diagnostics.